Genetic variants in CETP increase risk of intracerebral hemorrhage by Anderson, Christopher D. et al.
RESEARCH ARTICLE
Genetic Variants in CETP Increase Risk
of Intracerebral Hemorrhage
Christopher D. Anderson, MD, MMSc,1,2,3,4
Guido J. Falcone, MD, ScD, MPH,1,2,3,4,5 Chia-Ling Phuah, MD,1,2,3,4
Farid Radmanesh, MD, MPH,1,2,3,4 H. Bart Brouwers, MD,1,2,3,4
Thomas W. K. Battey, BS,1,2,3,4 Alessandro Biffi, MD,1,2,4,6,7
Gina M. Peloso, PhD,1,4 Dajiang J. Liu, PhD,8 Alison M. Ayres, BA,1,2
Joshua N. Goldstein, MD, PhD,9 Anand Viswanathan, MD, PhD,2
Steven M. Greenberg, MD, PhD,2 Magdy Selim, MD, PhD,10
James F. Meschia, MD,11 Devin L. Brown, MD, MS,12
Bradford B. Worrall, MD, MSc,13 Scott L. Silliman, MD,14
View this article online at wileyonlinelibrary.com. DOI: 10.1002/ana.24780
Received May 17, 2016, and in revised form Sep 13, 2016. Accepted for publication Sep 13, 2016.
Members of the International Stroke Genetics Consortium are available as an online supplementary file. Please refer to Supplementary Table 7 for con-
tributors and affiliations.
The copyright line for this article was changed on 21 November 2016 after original online publication.
Address correspondence to Dr Anderson, Center for Human Genetic Research, Massachusetts General Hospital, 185 Cambridge Street; CPZN-6818,
Boston, MA 02114. E-mail: cdanderson@mgh.harvard.edu
From the 1Center for Human Genetic Research, Massachusetts General Hospital (MGH), Boston, MA; 2J. Philip Kistler Stroke Research Center,
Department of Neurology, MGH, Boston, MA; 3Division of Neurocritical Care and Emergency Neurology, Department of Neurology, MGH, Boston, MA;
4Program in Medical and Population Genetics, Broad Institute, Cambridge, MA; 5Departments of Epidemiology and Biostatistics, Harvard T. H. Chan
School of Public Health, Boston, MA; 6Division of Behavioral Neurology, Department of Neurology, MGH, Boston, MA; 7Division of Psychiatry,
Department of Psychiatry, MGH, Boston, MA; 8Department of Public Health Sciences, Institute of Personalized Medicine, Penn State College of
Medicine, Hershey, PA; 9Department of Emergency Medicine, MGH, Boston, MA; 10Department of Neurology, Beth Israel Deaconess Medical Center,
Boston, MA; 11Department of Neurology, Mayo Clinic, Jacksonville, FL; 12Stroke Program, Department of Neurology, University of Michigan Health
System, Ann Arbor, MI; 13Departments of Neurology and Public Health Sciences, University of Virginia Health System, Charlottesville, VA; 14Department
of Neurology, University of Florida College of Medicine, Jacksonville, FL; 15Stroke Center, Harborview Medical Center, University of Washington,
Seattle, WA; 16Department of Neurology, University of Cincinnati College of Medicine, Cincinnati, OH; 17Department of Neurology, Jagiellonian
University Medical College, Krakow, Poland; 18Institute of Molecular Biology and Biochemistry, Medical University Graz, Graz, Austria; 19Division of
Neurology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; 20Division of Neurology, Department of Neurology and Rehabilitation
Medicine, Ska˚ne University Hospital, Lund, Sweden; 21Neurovascular Research Unit, Department of Neurology, Municipal Institute of Medical
Investigation–Hospital of the Sea, Autonomous University of Barcelona, Barcelona, Spain; 22Program in Inflammation and Cardiovascular Disorders,
Municipal Institute of Medical Investigation–Hospital of the Sea, Autonomous University of Barcelona, Barcelona, Spain; 23Department of Neurology
and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, the Netherlands; 24Department of Neurology, Donders
Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands; 25Division of Clinical Brain Sciences,
University of Edinburgh, Edinburgh, United Kingdom; 26Institute for Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United
Kingdom; 27Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, United Kingdom; 28Department of Clinical
and Experimental Sciences, Neurology Clinic, University of Brescia, Brescia, Italy; 29Department of Neurology, Medical University of Graz, Graz, Austria;
30Division of Neuroradiology, Department of Radiology, Medical University of Graz, Graz, Austria; 31Neurovascular Research Laboratory and
Neurovascular Unit, Research Institute, Vall d’Hebron Hospital, Autonomous University of Barcelona, Barcelona, Spain; 32Stroke Pharmacogenomics and
Genetics, Terrassa Mutual Teaching and Research Foundation, Terrassa Mutual Hospital, Terrassa, Spain; 33Department of Neurology, University of
Arizona, Tucson, AZ; 34Department of Neurology, Baltimore Veterans Administration Medical Center and University of Maryland School of Medicine,
Baltimore, MD; 35National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; 36Center for Public Health
Genomics and Department of Biostatistical Sciences, Wake Forest University, Winston-Salem, NC; 37Center for Statistical Genetics, Department of
Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI; 38Division of Cardiology, Department of Internal Medicine, University of
Michigan Medical School, Ann Arbor, MI; 39Department of Human Genetics, University of Michigan Medical School, Ann Arbor, MI; and
40Cardiovascular Disease Prevention Center, MGH, Boston, MA
Additional supporting information can be found in the online version of this article
730 VC 2016 The Authors. Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited.
David L. Tirschwell, MD, MSc,15 Matthew L. Flaherty, MD,16 Peter Kraft, PhD,5
Jeremiasz M. Jagiella, MD, PhD,17 Helena Schmidt, MD,18
Bj€orn M. Hansen, MD,19,20 Jordi Jimenez-Conde, MD, PhD,21,22
Eva Giralt-Steinhauer, MD,21,22 Roberto Elosua, MD, PhD,21,22
Elisa Cuadrado-Godia, MD,21,22 Carolina Soriano, PhD, BSc,21,22
Koen M. van Nieuwenhuizen, MD,23 Catharina J. M. Klijn, MD, PhD,23,24
Kristiina Rannikmae, MD,25 Neshika Samarasekera, PhD, MRCP,25
Rustam Al-Shahi Salman, MA, PhD, FRCP,25
Catherine L. Sudlow, BMBCh, MSc, DPhil, FRCPE,25,26
Ian J. Deary, FBA, FRSE, FMedSci,27 Andrea Morotti, MD,28
Alessandro Pezzini, MD,28 Joanna Pera, MD,17 Andrzej Urbanik, MD, PhD,17
Alexander Pichler, MD,29 Christian Enzinger, MD,29,30 Bo Norrving, MD,19,20
Joan Montaner, MD, PhD,31 Israel Fernandez-Cadenas, PhD,31,32
Pilar Delgado, MD, PhD,31 Jaume Roquer, MD, PhD,21,22 Arne Lindgren, MD,19,20
Agnieszka Slowik, MD, PhD,17 Reinhold Schmidt, MD,29 Chelsea S. Kidwell, MD,33
Steven J. Kittner, MD, MPH,34 Salina P. Waddy, MD,35 Carl D. Langefeld, PhD,36
Goncalo Abecasis, PhD,37 Cristen J. Willer, PhD,38,39 Sekar Kathiresan, MD,1,4,40
Daniel Woo, MD,16 and Jonathan Rosand, MD, MSc,1,2,3,4
on behalf of the Global Lipids Genetics Consortium and International
Stroke Genetics Consortium
Objective: In observational epidemiologic studies, higher plasma high-density lipoprotein cholesterol (HDL-C) has
been associated with increased risk of intracerebral hemorrhage (ICH). DNA sequence variants that decrease choles-
teryl ester transfer protein (CETP) gene activity increase plasma HDL-C; as such, medicines that inhibit CETP and
raise HDL-C are in clinical development. Here, we test the hypothesis that CETP DNA sequence variants associated
with higher HDL-C also increase risk for ICH.
Methods: We performed 2 candidate-gene analyses of CETP. First, we tested individual CETP variants in a discovery
cohort of 1,149 ICH cases and 1,238 controls from 3 studies, followed by replication in 1,625 cases and 1,845 con-
trols from 5 studies. Second, we constructed a genetic risk score comprised of 7 independent variants at the CETP
locus and tested this score for association with HDL-C as well as ICH risk.
Results: Twelve variants within CETP demonstrated nominal association with ICH, with the strongest association at
the rs173539 locus (odds ratio [OR]5 1.25, standard error [SE]5 0.06, p5 6.03 1024) with no heterogeneity across
studies (I250%). This association was replicated in patients of European ancestry (p5 0.03). A genetic score of CETP
variants found to increase HDL-C by 2.85mg/dl in the Global Lipids Genetics Consortium was strongly associated
with ICH risk (OR5 1.86, SE5 0.13, p5 1.3931026).
Interpretation: Genetic variants in CETP associated with increased HDL-C raise the risk of ICH. Given ongoing thera-
peutic development in CETP inhibition and other HDL-raising strategies, further exploration of potential adverse
cerebrovascular outcomes may be warranted.
ANN NEUROL 2016;80:730–740
Serum levels of high-density lipoprotein cholesterol(HDL-C) are strongly and inversely associated with
coronary artery disease (CAD) risk.1 Of the many single
nucleotide polymorphisms (SNPs) associated with HDL-
C levels, those within cholesteryl ester transfer protein
(CETP) have the strongest effect.2–4 Inhibitory variants
within CETP associated with increased HDL-C correlate
with reduced risk of multiple cardiac risk factors, includ-
ing metabolic syndrome and myocardial infarction.5–8
Inhibitors of the CETP gene product, designed to raise
HDL-C by limiting CETP-mediated exchange of choles-
teryl esters and triglycerides between HDL and low-
density lipoprotein (LDL)/very low-density lipoprotein
particles, are being investigated in ongoing phase III trials
as treatments to reduce CAD risk.9,10
In contrast, substantial data suggest that elevations
in HDL-C may increase risk of spontaneous intracerebral
hemorrhage (ICH).11,12 Furthermore, clinical trial data
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suggest an increased risk of ICH on statins despite a lack
of significant differences in lipid levels.13,14 Because of
small sample sizes and confounding by environmental or
medical exposures, prior studies have not been able to
resolve this potentially paradoxical role of elevated HDL-
C in ICH. Although ICH comprises only 15 to 20% of
all strokes, it accounts for 50% of all stroke-related mor-
tality and 30% of total costs.15,16 Blood pressure control
remains the only available preventive strategy.17 As
HDL-C evolves as a cardiovascular treatment target and
clinical trial data on therapeutic modifiers accrue, an
improved mechanistic understanding of the pathways
involved in hemorrhagic cerebrovascular disease could
lead to alternative treatments and prevention strategies
for ICH.
It is not known whether CETP inhibitors, which
endeavor to produce a biological effect similar to known
genetic variants in CETP, increase ICH risk. The objec-
tive of this study was to use genome-wide genotypes
from individuals with and without ICH from the Inter-
national Stroke Genetics Consortium (ISGC) to test
genetic variants within CETP for association with ICH
risk, under the hypothesis that the HDL-raising effects of
inhibitory variants within CETP will result in increased
ICH. CETP genetic variants that impact HDL-C are
unconfounded by other exposures, remain constant
throughout life, and may be more reflective of long-term
levels than periodic lipid measurements.18 Thus, exami-
nation of CETP genetic variation constitutes a valuable
causal inference tool to help strengthen or disclaim prior
observations of association between elevated HDL-C and
ICH, and could provide additional clues about potential
adverse effects of pharmacologic CETP inhibition.
Materials and Methods
Study Design
We performed a 2-stage (discovery and replication) case–control
candidate-gene association study using both genome-wide data
and direct genotyping. The discovery phase utilized data from
3 genome-wide association studies (GWASs) of ICH, sampling
patients of European ancestry (Table 1).19 Replication involved
direct genotyping of variants of interest from individuals
recruited through 5 case–control studies of ICH, with no over-
lap between individuals from the discovery phase (Table 2).
Detailed description of discovery and replication case and con-
trol recruitment architectures can be found in Supplementary
Table 1.
All studies had approval from the local institutional
review board or ethics committee at each participating institu-
tion. Informed consent was obtained from all patients or their
legally authorized representatives, or was waived via protocol-
specific allowance.
Cases
ICH was defined as a new and acute neurological deficit with
compatible brain imaging. Enrolled patients were adult consent-
ing primary acute ICH cases that presented to participating insti-
tutions with confirmation of primary ICH through computed
tomography or magnetic resonance imaging. Exclusion criteria
included trauma, brain tumor, hemorrhagic transformation of a
TABLE 1. Discovery Populations
GOCHA ISGC ICH Study GERFHS
Variable Cases Controls Cases Controls Cases Controls
No. 371 389 404 530 374 319
Age, mean (SD) 74 (10) 72 (8) 70 (13) 66 (16) 67 (15) 67 (14)
Female, No. [%] 172 [46] 195 [50] 189 [47] 266 [50] 194 [52] 172 [54]
HTN, No. [%] 274 [75] 227 [58] 278 [69] 247 [47] 241 [64] 166 [52]
T2D, No. [%] 68 [18] 35 [9] 89 [22] 68 [13] 72 [19] 42 [13]
HL, No. [%] 144 [39] 195 [50] 87 [22] 48 [9] 131 [35] 133 [42]
Smoking, No. [%] 56 [15] 15 [4] 58 [14] 74 [14] 79 [21] 46 [14]
Genotyping platform Illumina 610 Illumina 610 Illumina 610 Illumina 610 Affymetrix 6.0 Affymetrix 6.0
Lobar,a No. [%] 205 [55] – 135 [33] – 156 [42] –
Discovery totals: 2,387 individuals (1,149 cases, 1,238 controls), 43% lobar ICH.
aLobar ICH location.
GERFHS5Genetic and Environmental Risk Factors for Hemorrhagic Stroke study; GOCHA5Genes and Outcomes of Cerebral Hemorrhage on
Anticoagulation study; HL5 hyperlipidemia; HTN5 hypertension; ICH5 intracerebral hemorrhage; ISGC5 International Stroke Genetics Con-
sortium; SD5 standard deviation; T2D5 type 2 diabetes mellitus.
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cerebral infarction, vascular malformation, or any other cause of
secondary ICH in all participating studies.
CASE POPULATIONS. ICH cases were recruited across multi-
ple centers participating in the ISGC from sites in the USA
and Europe. For the purposes of reducing confounding by pop-
ulation stratification, only individuals of self-reported European
(Caucasian) ancestry were included in the analysis. Likewise,
several studies (Genetics of Cerebral Hemorrhage with Anticoa-
gulation, Edinburgh Stroke Study, LINCHPIN) recruited ICH
patients with ICH in the presence of anticoagulation (typically
warfarin) exposure. These individuals were excluded from analy-
ses due to the etiopathological distinctness of warfarin-related
primary ICH from other forms. Discovery case populations
were enrolled according to methods previously described.19
Replication cases were recruited from ISGC participating cen-
ters using similar criteria as discovery cases (Supplementary
Table 2). Briefly, the University Medical Center (UMC)
Utrecht ICH study included additional screening for secondary
ICH cases in follow-up. The Edinburgh Stroke Study recruited
subjects aged >55 years only, and specifically excluded individ-
uals with antecedent illicit drug use or presentation >1 week
from onset of symptoms. The LINCHPIN study identified
ICH cases aged >16 years with acute or chronic ICH from a
prospective cohort of individuals living in the Lothian region of
Scotland, United Kingdom.
NEUROIMAGING. Stroke neurologists and neuroradiologists
at each participating site performed the neuroimaging assess-
ment. Following known differences in underlying biology, ICH
was classified as lobar or nonlobar according to location.20 ICH
originating in the corticosubcortical junction (with or without
involvement of subcortical white matter) was defined as lobar,
whereas ICH selectively involving the thalamus, internal cap-
sule, basal ganglia, brainstem, or cerebellum was defined as
nonlobar.
Controls
Controls were ICH-free individuals>18 years of age and were
enrolled from the same populations that gave rise to the cases.
Controls were confirmed to have no history of previous ICH
by interview and/or medical record review. Control population
age restrictions were identical to case population age restrictions
for all included studies.
CONTROL POPULATIONS. ICH-free controls were recruited
from the same populations that gave rise to the ICH cases,
through inpatient recruitment, ambulatory centers in the local
communities, blood donation centers serving the same popula-
tion, and in the case of the Lothian Birth Cohort, a population
cohort study (Supplementary Table 3). The Genetic and Envi-
ronmental Risk Factors for Hemorrhagic Stroke (GERFHS)
and Ethic/Racial Variations of Intracerebral Hemorrhage
(ERICH) studies19,21 used random digit dialing, the Lothian
Birth Cohort individuals were matched to case samples by local
investigators,22 and UMC Utrecht identified controls from the
local blood donor population. The remainder of the studies
used random selection from ambulatory clinics or geographical-
ly matched populations where cases were being recruited.
Exposure: Common Genetic Variants
within CETP
In the discovery phase, we ascertained variants within CETP by
means of genome-wide genotyping followed by imputation
using methods and quality control procedures previously
described.19 Briefly, DNA was isolated from fresh or frozen
peripheral whole blood collected from cases and controls at
each participating institution at the time of consent, quantified
with a quantification kit (Qiagen, Valencia, CA), and normal-
ized to a concentration of 30ng/ll. Cases and controls were
plated together and genotyped on Illumina (San Diego, CA)
610 or Affymetrix (Santa Clara, CA) 6.0 platforms. Standard
quality controls for genome-wide data were applied, and the
TABLE 2. Replication Populations
MGH ERICH
University of
Brescia UMC Utrecht
University of
Edinburgh
Variable Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls
No. 240 458 920 826 198 185 157 160 110 216
Age, No. (SD) 76 (10) 69 (11) 69 (14) 68 (13) 69 (13) 63 (14) 62 (13) 56 (11) 75 (9) 76 (10)
Female, No. [%] 96 [40] 206 [45] 397 [43] 371 [45] 81 [41] 85 [46] 66 [42] 67 [42] 59 [54] 118 [54]
Lobar, No. [%] 120 [48] – 380 [41] – 82 [41] – 60 [38] – 61 [55] –
Genotyping platform iPLEX iPLEX Taqman Taqman iPLEX iPLEX iPLEX iPLEX iPLEX iPLEX
Replication totals: 3,470 individuals (1,625 cases, 1,845 controls), 42% lobar ICH. Discovery1 replication totals: 5,625 individuals (2,595 cases,
3,030 controls), 45% lobar ICH.
ERICH5Ethnic/Racial Variations of Intracerebral Hemorrhage; ICH5 intracerebral hemorrhage; iPLEX5 Sequenom MassARRAY iPLEX Plat-
form; MGH5Massachusetts General Hospital; SD5 standard deviation; TaqMan5Applied Biosystems Taqman Genotyping Assay;
UMC5University Medical Center.
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resulting set of individuals and SNPs were carried forward to
imputation, which was completed using IMPUTE2 with 1000
Genomes–based reference panels (March 2012 version).23 Post-
imputation exclusion filters were minor allele frequency
(MAF)< 0.01 and information score< 0.5. SNPs were
extracted from the CETP gene region according to the human
genome reference GRCh38.p2 annotated location (http://www.
ncbi.nlm.nih.gov),6 50 kilobases.
Independent Replication
CETP variants exceeding Bonferroni-corrected significance and
without significant heterogeneity (I2< 40%) for association
with ICH in the discovery phase were selected for replication.24
Replication SNPs were chosen based on proxy status with index
SNPs. Because replication of CETP variants was carried out as
part of an ongoing GWAS of ICH, a constraint for the selec-
tion of replication SNPs was predicted genotyping success using
iPLEX (Sequenom, San Diego, CA) and Taqman (Applied Bio-
systems, Foster City, CA) methodologies, which were employed
at the Massachusetts General Hospital and University of Miami
genotyping centers, respectively (see Table 2). Ancestry-
informative markers were also genotyped to facilitate adjust-
ment for population admixture.
Data Analysis
We present discrete variables as counts (percentage) and contin-
uous variables as mean (standard deviation [SD]) or median
(interquartile range), as appropriate.
POPULATION STRUCTURE. Principal component analysis
was implemented in both discovery and replication to account
for population structure, using genome-wide data in discovery
and prespecified ancestry-informative markers in replica-
tion.25,26 Caucasian population outliers were identified and
removed by visual inspection of plots generated with principal
components 1 and 2, and these principal components were
included as covariates in regression models fitted for association
testing. In the GERFHS and ERICH samples, further refine-
ment of population structure was achieved using the ADMIX-
TURE software tool to remove outliers.27
ASSOCIATION TESTING. Prior to discovery association test-
ing, SNPs within CETP were clumped into loci sharing linkage
disequilibrium (LD) r2> 0.5 using PLINK to allow discrimina-
tion of semi-independent loci across the gene. Association testing
for SNPs within the CETP locus and ICH risk was completed
separately for all ICH, as well as for lobar and nonlobar hemor-
rhages. Logistic regression models were fitted assuming indepen-
dent additive genetic effects for dosage of the minor allele (1
degree of freedom additive trend test), and adjusted for age, gen-
der, and principal components 1 and 2. A similar analytic
approach was undertaken for analysis of replication data, using
additive allele genotype data rather than dosage.
META-ANALYSIS. Fixed effects, inverse variance weighted
meta-analysis was used to pool effect estimates across studies,
assessing heterogeneity by computing Cochrane’s Q (with corre-
sponding p) and I2 (percentage of effect size attributable to
heterogeneity). Identical meta-analysis procedures were used for
pooling of effects across studies in discovery and replication,
and across all studies.28
Genetic Risk Score Analysis
Variants within the CETP locus with established association
with HDL-C levels in the most recent Global Lipids Genetics
Consortium (GLGC) analysis (unpublished data) were extracted
from the discovery data set and tested for association with ICH
using an additive multi-SNP genetic risk score approach using
the GTX package (http://CRAN.R-project.org/package5gtx) in
R (version 3.0). Ten variants surpassing exome array-wide sig-
nificance (p< 2.13 1027) and demonstrating independence
using a sequential forward selection model in the GLGC data
set were identified, of which 7 were available in our ICH dis-
covery data set.29 These 7 variants, on average, were associated
with a 0.19-SD increase in HDL-C (2.85mg/dl) in the
GLGC population (p< 13 102200). This corresponds to a pro-
portion of variance explained of 0.032. ICH risk was predicted
from summary statistics, weighted according to the established
HDL-C effect, and oriented to the HDL-C increasing allele.
Statistical Testing and Software
We used a conservative Bonferroni-corrected threshold for statis-
tical significance of p< 0.004, adjusted for the number of semi-
independent loci within CETP with r2< 0.5 (12 tests in this
analysis). Quality control procedures, genetic association testing
for single variants, and score calculations were performed in
SNPTest and PLINK v1.07.26,30 Imputation was completed using
IMPUTE2.23 All other statistical analyses were performed in SAS
9.2 (SAS Institute, Cary, NC).
Results
Following relevant exclusions during quality control and
principal component analysis, 1,149 ICH cases and
1,238 controls from 3 case–control studies of ICH were
included in the discovery phase, 43% of which were of
the lobar ICH subtype (see Table 1).
CETP Genetic Variants
After imputation using 1000 Genomes reference panels
and application of genome-wide quality control filters, a
total of 390 common variants of MAF> 0.01 were
extracted from the CETP gene and 50kb flanking regions
(Supplementary Table 4).31 These 390 variants were pre-
sent either via array-based ascertainment or imputation
in all 3 of the discovery data sets, and were used for asso-
ciation testing.
Single-SNP Association Testing
After testing all 390 SNPs within CETP clumped into
regions sharing r2> 0.5, 12 loci demonstrating nominal
association with ICH (p< 0.05) were identified (Supple-
mentary Table 5). Three of these loci surpassed Bonfer-
roni correction (Table 3) with residual r25 0.25 to 0.39
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between them. Among these, only rs173539 (odds ratio
[OR]5 1.25, standard error [SE]5 0.06, p5 6.003
1024) met prespecified criteria for replication due to its
homogeneity across discovery data sets (I25 0%). Of
note, rs173539 was in high LD with rs3764261 (r25
0.98), the strongest associated SNP with HDL-C in pub-
lished GWASs of lipid levels (Fig 1).32 Comparison of
effects of the rs173539 locus on risk of lobar versus non-
lobar hemorrhage revealed no significant differences by
ICH subtype (Supplementary Table 6).
Replication and Meta-Analysis
of the rs173539 Locus
A total of 1,625 ICH cases and 1,845 controls of Cauca-
sian ancestry were available for replication. Following
application of predictive algorithms for SNP genotype
ascertainment success using both genotyping methodolo-
gies employed, 4 SNPs in LD with rs173539 locus were
selected for replication genotyping according to the con-
straints described (Tables 4 and 5). Both rs173539 and
rs3764261 were predicted to fail in one or both replica-
tion pools. All 4 selected SNPs were successfully geno-
typed in all replication data sets. All replication results
showed minimal heterogeneity and consistent directions
of effect, and 2 variants replicated at p< 0.05. In meta-
analysis, all 4 SNPs within the rs173539 locus chosen for
replication were strengthened by addition of the replica-
tion SNP data, with minimal heterogeneity in the final
total sample size of 2,595 ICH cases and 3,030 controls
(see Table 5).
Genetic Risk Score Analysis
An additive multi-SNP genetic risk score was constructed
using independent HDL-association data.29 Ten variants
were selected, of which 7 were present in the ICH dis-
covery data set (Table 6). Three variants were unavailable
in the ICH data set due to differences in genotyping
platforms (exome array vs GWAS array) between the two
studies. The genetic risk score of these 7 variants demon-
strated association with ICH (OR5 1.86, SE5 0.13,
p5 1.393 1026).
Discussion
Our results demonstrate an association between CETP
gene variants in the rs173539 locus and risk of ICH,
opposite in direction from their effect on risk of CAD
and metabolic syndrome.5,7,8 Furthermore, an aggregated
score of variants within CETP that raise HDL-C is
FIGURE 1: Regional association plot of rs173539 and single nucleotide polymorphisms (SNPs) exhibiting r2>0.5 in association
with intracerebral hemorrhage. SNPs available for replication are circled. Mean recombination rate across the locus is repre-
sented by the continuous line. The rs3764261 variant identified was the leading SNP in prior genome-wide association studies
of high-density lipoprotein cholesterol. chr5 chromosome; cM5 centimorgans; Mb5megabase. [Color figure can be viewed in
the online issue, which is available at www.annalsofneurology.org.]
TABLE 3. Discovery CETP Loci Demonstrating Bonferroni-Significant Association with ICH
Lead SNP CHR Tested Allele MAF Effect Direction OR SE Discovery p I2
rs173539 16 T 0.31 111 1.25 0.06 6.00E-4 0
rs820299 16 G 0.38 222 0.81 0.06 7.50E-4 48
rs158478 16 A 0.48 111 1.21 0.06 1.48E-3 56
15 variant increases ICH risk; 25 variant decreases ICH risk; CHR5 chromosome; ICH5 intracerebral hemorrhage; MAF5minor allele fre-
quency; OR5 odds ratio; SE5 standard error; SNP5 single nucleotide polymorphism.
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strongly associated with increased ICH risk. These results
suggest that there may be substantial differences in the
roles of lipids in the progression of cerebrovascular and
cardiometabolic diseases. Novel therapies targeting CETP
along with other approaches to increase HDL-C are cur-
rently under active investigation in an effort to reduce
the risk of CAD.33 Because the cerebral small vessel dis-
eases that lead to ICH are common in the aging popula-
tion and frequently coincide with risk factors for
cardiometabolic disease,34,35 our observations supporting
opposing effects of HDL-C on ICH and CAD under-
score the need for a better understanding of which
patients could be at increased risk of ICH on therapies
aimed at increasing HDL-C.
Our findings support prior studies linking elevated
HDL-C with increased risk of ICH. Unlike prior studies,
however, our genetic approach limits confounding by
dietary, environmental, or medication exposures. A recent
meta-analysis of epidemiological studies examining asso-
ciations between cholesterol levels and ICH found a
dose–response relationship between HDL-C and ICH
risk, with each 1mmol/l increase in HDL-C associated
with a 17% increase in ICH risk.11 This result was nulli-
fied when studies of subarachnoid hemorrhage patients
were included, but strengthened by restriction to studies
from the United States, highlighting the potential con-
founds of case misspecification and unmeasured environ-
mental exposures in testing associations of this nature.
HDL-C appears to have a complex and context-
dependent role in cerebrovascular disease. In contrast to
ICH, elevated HDL-C is associated with reduced risk of
ischemic stroke, particularly strokes caused by large artery
atherosclerotic disease, consistent with the observed asso-
ciations of HDL-C in CAD.36 However, Mendelian ran-
domization (MR) studies of genetic variants predisposing
to elevated HDL-C have not demonstrated association
with either ischemic stroke or CAD, suggesting the
observed relationships may not be causal.37,38 Unfortu-
nately, the limited sample size of genetics efforts in ICH
coupled with acute changes in lipid values around the
TABLE 4. Discovery SNP rs173539 and Local Proxies in Association with ICH Risk
SNP CHR Tested Allele MAF Effect
Direction
OR SE Discovery p I2
rs173539 16 T 0.31 111 1.25 0.06 6.003 1024 0
2rs247617, r25 0.99 16 A 0.31 111 1.24 0.06 8.743 1024 0
2rs17231506, r25 0.99 16 T 0.31 111 1.23 0.06 9.133 1024 0
2rs711752, r25 0.62 16 A 0.42 112 1.15 0.06 2.083 1022 14
2rs708272, r25 0.61 16 A 0.42 112 1.15 0.06 2.233 1022 18
Association results for rs173539 in association with ICH risk, as well as 4 additional SNPs in LD with rs173539 chosen for replication.
25 variant decreases ICH risk;15 variant increases ICH risk; CHR5 chromosome; ICH5 intracerebral hemorrhage; LD5 linkage disequilibri-
um; MAF5minor allele frequency; OR5 odds ratio; r25 degree of LD with rs173539; SE5 standard error; SNP5 single nucleotide
polymorphism.
TABLE 5. Replication Results for SNPs in Linkage Disequilibrium with rs173539 and Meta-Analysis of All
Samples
Replication Discovery/Replication Meta-Analysis
SNP Effect OR SE p I2 Effect OR SE p I2
rs247617 11111 1.08 0.05 0.18 2 111/11111 1.13 0.04 1.03 1023 0
rs17231506 11111 1.08 0.05 0.17 1 111/11111 1.13 0.04 1.03 1023 0
rs711752 11112 1.12 0.05 0.03 7 112/11112 1.13 0.04 1.03 1023 0
rs708272 11112 1.14 0.05 0.01 4 112/11112 1.14 0.04 5.03 1024 0
15 variant increases ICH risk; 25 variant decreases ICH risk; ICH5 intracerebral hemorrhage; OR5 odds ratio; SE5 standard error;
SNP5 single nucleotide polymorphism.
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time of ICH currently preclude the use of this MR
approach in our analyses.39
No study, including the present, has yet established
a direct causal relationship between HDL-C and ICH
risk. Although associations between CETP genetic var-
iants and ICH are almost certainly unidirectional due to
the immutability of the genetic code, they still could
impact an unseen risk factor that lies outside of the
known HDL-C level determining effects of the gene.
Even if causality can be ultimately established, the mech-
anism by which a CETP-mediated increase in HDL-C
may worsen ICH risk remains unclear. Inhibition of
CETP results in changes to HDL particle size and cho-
lesterol efflux capacity in addition to the observed
changes in HDL-C serum levels, and it may be through
these accompanying changes in HDL function that ICH
risk is conferred.40 Furthermore, accumulating evidence
suggests that HDL effects on endothelium are dynamic
and modifiable, and can even become proinflammatory
with the incorporation of serum amyloid A1, comple-
ment C3, and ceramides, resulting in altered immune
regulation and reduced antioxidant effects.41,42 It is
therefore possible that elevated HDL-C provides a plat-
form to further the vascular inflammatory processes that
play a substantial role in the cerebral small vessel disease
underlying ICH.43 Further studies will be needed to dis-
sect the pathways intersecting with HDL-C to clarify the
foundational biology of its role in ICH.
Therapeutic development of small molecule and
biologic compounds designed to raise HDL-C contin-
ue.44 Although the first wave of phase III trials of CETP
inhibitors were plagued by off-target effects and futility,45
the REVEAL trial of anacetrapib was recently continued
after unblinded interim review. Other HDL-raising strat-
egies, including apolipoprotein-A1 (ApoA1)-rich reconsti-
tuted HDL particle infusions and ApoA1-mimetic
peptides, continue to be evaluated in preclinical and early
phase trials.44 Given this pipeline of HDL-based thera-
peutic development, it is imperative that potential
adverse clinical effects of such strategies be clarified. Early
experiences with US Food and Drug Administration–
approved PCSK-9 inhibitors have led to predictions of
widespread adoption of this new class of drugs, and it is
reasonable to expect that HDL-C targeted treatments
would be no different, resulting in a potentially large
population of aging individuals with pharmacologically
induced high HDL-C levels of uncertain long-term cere-
brovascular risk.46 The proportion of variance in HDL-C
levels explained by our genetic risk score was 0.032. This
is roughly commensurate with observed effects of statins,
which in clinical trials raised HDL by 0.04 to 0.10mg/
dl.47 With emerging HDL-C modifying strategies likely
to exert more profound effects, the impact on ICH risk,
if confirmed and verified to be causal, could be more
substantial than indicated by our CETP genetic risk
score.
As noted above, our study cannot determine wheth-
er the observed association between CETP and ICH risk
is through HDL-C alone. Although they exhibit their
largest effect on HDL-C levels, CETP variants are also
associated with LDL, triglycerides, and total cholesterol
levels.3 Although we cannot perform formal MR, the
association between our HDL-C increasing genetic risk
score at CETP and risk of ICH provides support for an
HDL-specific effect. Even with this suggestion of HDL-
C specificity, the composition of HDL particles can vary
TABLE 6. ICH Association Results for Variants of Known HDL-C Effect Used to Compute Genetic Risk Score
SNP Ref
Allele
MAF ICH OR ICH Beta ICH SE ICH p HDL
Effect
Allele
HDL
Beta
HDL SE Type
rs173539 T 0.31 1.25 0.222 0.065 0.0006 T 0.230 0.0028 Intergenic
rs3764261 A 0.31 1.23 0.210 0.063 0.0009 A 0.239 0.0028 Intergenic
rs247616 T 0.30 1.22 0.196 0.064 0.0023 T 0.242 0.0028 Intergenic
rs9989419 A 0.40 0.92 20.079 0.059 0.1808 G 0.131 0.0026 Intergenic
rs5880 C 0.04 1.22 0.202 0.151 0.1812 G 0.258 0.0067 Nonsyn.
rs5882 G 0.32 1.06 0.057 0.065 0.3803 G 0.092 0.0028 Nonsyn.
rs7499892 T 0.19 1.02 0.022 0.076 0.7758 C 0.230 0.0033 Intronic
HDL-C5 high-density lipoprotein cholesterol; ICH5 intracerebral hemorrhage; MAF5minor allele frequency; Nonsyn.5 nonsynonymous;
OR5 odds ratio; Ref5 reference; SE5 standard error; SNP5 single nucleotide polymorphism.
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with respect to ratios of esterified to unesterified choles-
terol as well as apolipoprotein content. Genetic variation
that determines circulating HDL-C does not necessarily
capture these secondary characteristics, which could have
a substantial impact on biological effects.
An additional limitation of our study is the aggrega-
tion of case and control data across multiple sites, which
could result in biases between cases and controls. We have
attempted to control for study demographics and popula-
tion structure in our regression analyses, and performed
independent replication, but unmeasured confounding
could still have impacted the observed associations. Related
to this point, all analyses presented were in individuals of
European ancestry due to small study populations, and
therefore low statistical power, in individuals of other racial
and ethnic backgrounds. As a result, our findings cannot be
extended to minority populations at this time.
Although our study utilized genome-wide data for
discovery and genetic risk score analyses, our approach
was fundamentally a candidate gene study of CETP.
Using GWAS data allowed for control of population
stratification, which can be a major confounder in tradi-
tional candidate gene designs employing only direct gen-
otyping. However, it was still based on an a priori
hypothesis about CETP association with ICH. Therefore,
the false discovery rate for association between variants at
CETP and ICH risk, although stringently controlled
using Bonferroni correction at the CETP locus, may still
be elevated in comparison with a standard GWAS. Due
to the hypothesis-driven nature of our study, we by defi-
nition cannot provide novel results about lipid-related
genetic loci that lie outside of the tested gene region.
Finally, the CETP gene contains several independent
loci which have been associated with lipid levels and clini-
cal endpoints.3,5,7,32 This resulted in a more complex repli-
cation phase than would have been needed if the genetic
architecture of the locus were centered about a single
region of association. Coupled with the limitations of vari-
ant selection in our replication phase, we cannot distin-
guish a culprit variant to the exclusion of others. Although
all variants chosen for replication demonstrated refined
effect size estimates and greater statistical significance in
meta-analysis with discovery data, replication was strongest
for variants in slightly lower LD than the lead variant from
discovery, and with slightly higher between-study heteroge-
neity. Whether this observation represents true heterogene-
ity of effect at the replicated variants will depend on future
validation and extension studies.
We have demonstrated an association between
genetic variants in CETP and risk of ICH, and have
shown that CETP’s HDL-C raising effects could play a
role in the pathogenesis of ICH. Further work will be
needed to identify how the biological pathways impacted
by HDL-C may impart increased risk of hemorrhage.
These pathways may yield crucial novel targets for pre-
vention of ICH and the cerebral small vessel diseases that
lead to vessel rupture.
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